Natural Compounds in Pediatric Disease Treatment
Abstract
The review evaluates current clinical and epidemiological evidence regarding the use of plant-derived compounds in pediatric practice. Data from randomized controlled trials indicate symptomatic efficacy of selected agents-particularly in acute respiratory infections-alongside generally favorable safety profiles when standardized preparations are used. Emerging research also explores applications in neurodevelopmental disorders, gastrointestinal conditions, and dermatology, and as supportive therapy in pediatric oncology. However, variability in product quality, limited pediatric-specific trials, potential toxicity, and regulatory inconsistencies remain significant challenges. The integration of phytotherapy into pediatric care therefore requires rigorous study design, careful safety monitoring, and clear quality standards to ensure an evidence-based risk-benefit balance.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.